224:236–240.
619 Singh, A., S.E. Boston, and R. Poma. 2010. Thymoma‐associated exfoliative dermatitis with post‐thymectomy myasthenia gravis in a cat. Can Vet J 51:757–760.
620 Sivacolundhu, R.K., J.J. Runge, T.A. Donovan, et al. 2013. Ulnar osteosarcoma in dogs: 30 cases (1992–2008). J Am Vet Med Assoc 243:96–101.
621 Skorupski, K.A., C.A. Clifford, M.C. Paoloni, et al. 2007. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med 21:121–126.
622 Skorupski, K.A., C.O. Rodriguez, E.L. Krick, et al. 2009. Long‐term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy. Vet Comp Oncol 7:139–144.
623 Skorupski, K.A., J.M. Uhl, A. Szivek, et al. 2016. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: A randomized, phase III trial. Vet Comp Oncol 14(1):81–87.
624 Slawienski, M.J., G.E. Mauldin, G.N. Mauldin, et al. 1997. Malignant colonic neoplasia in cats: 46 cases (1990–1996). J Am Vet Med Assoc 211:878–881.
625 Sleeckx, N., H. De Rooster, E.J. Veldhuis Kroeze, et al. 2011. Canine mammary tumours, an overview. Reprod Domest Anim 46:1112–1131.
626 Smith, J., M. Kiupel, J. Farrelly, et al. 2017. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone. Vet Comp Oncol 15:36–45.
627 Smith, J.D., E.A. Stone, and S.D. Gilson. 1995. Placement of a permanent cystostomy catheter to relieve urine outflow obstruction in dogs with transitional cell carcinoma. J Am Vet Med Assoc 206:496–499.
628 Smith, A.N., J.C. Wright, W.R. BrawnerJr., et al. 2001. Radiation therapy in the treatment of canine and feline thymomas: A retrospective study (1985–1999). J Am Anim Hosp Assoc 37:489–496.
629 Song, T., W. Wang, P. Liu, et al. 2009. Pharmacokinetic comparison between pelvic transarterial chemoembolization and transcatheter arterial chemotherapy in an animal model. Mol Med Rep 2:663–667.
630 Sorenmo, K.U., J.L. Baez, C.A. Clifford, et al. 2004a. Efficacy and toxicity of a dose‐intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med 18:209–213.
631 Sorenmo, K., L. Duda, L. Barber, et al. 2000a. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med 14:395–398.
632 Sorenmo, K.U., M.H. Goldschmidt, F.S. Shofer, et al. 2004b. Evaluation of cyclooxygenase‐1 and cyclooxygenase‐2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol 2:13–23.
633 Sorenmo, K.U., K.A. Jeglum, and S.C. Helfand. 1993. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 7:370–376.
634 Sorenmo, K.U., E. Krick, C.M. Coughlin, et al. 2011. CD40‐activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non‐Hodgkin's lymphoma. PLoS One 6:e24167.
635 Sorenmo, K., B. Overley, E. Krick, et al. 2010. Outcome and toxicity associated with a dose‐intensified, maintenance‐free CHOP‐based chemotherapy protocol in canine lymphoma: 130 cases. Vet Comp Oncol 8:196–208.
636 Sorenmo, K.U., M. Samluk, C.A. Clifford, et al. 2005. Efficacy and toxicity of intracavitary administration of pegylated liposomal encapsulated doxorubicin (Doxil) in dogs with haemangiosarcoma. Vet Comp Oncol 3(1):55–56.
637 Sorenmo, K.U., F.S. Shofer, and M.H. Goldschmidt. 2000b. Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. J Vet Intern Med 14:266–270.
638 Sorenmo, K.U., D.R. Worley, and M.H. Goldschmidt. 2013. 27 – Tumors of the mammary gland. In Withrow and MacEwen's Small Animal Clinical Oncology, 5th edition. R.L. Page, S.J. Withrow, and D.M. Vail, editors. St. Louis: W.B. Saunders.
639 Spangler, W.L. and M.R. Culbertson. 1992. Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985–1989). J Am Vet Med Assoc 200:829–834.
640 Spangler, W.L. and P.H. Kass. 1997. Pathologic factors affecting postsplenectomy survival in dogs. J Vet Intern Med 11:166–171.
641 Sparkes, A., S. Murphy, F. McConnell, et al. 2005. Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma. J Feline Med Surg 7:313–316.
642 Spodnick, G.J., J. Berg, W.M. Rand, et al. 1992. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 200:995–999.
643 Spugnini, E.P. 2002. Use of hyaluronidase for the treatment of extravasation of chemotherapeutic agents in six dogs. J Am Vet Med Assoc 221:1437–1440, 1419–1420.
644 Spugnini, E.P., T. Azzarito, and S. Fais. 2016. Electrochemotherapy as first line cancer treatment: Experiences from veterinary medicine in developing novel protocols. Curr Drug Targets 16:43–52.
645 Spugnini, E.P. and A. Baldi. 2019. Electrochemotherapy in veterinary oncology: State if the art and perspectives. Vet Clin North Am 49:967–979.
646 Spugnini, E.P., A. Baldi, and B. Vincenzi. 2007. Intraoperative versus postoperative electrochemotherapy in high‐grade soft tissue sarcomas: A preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol 59:375–381.
647 Spugnini, E.P., S. Crispi, A. Scarabello, et al. 2008. Piroxicam and intracavitary platinum‐based chemotherapy for the treatment of advanced mesothelioma in pets: Preliminary observations. J Exp Clin Cancer Res 27:6.
648 Spugnini, E.P., E. Dragonetti, B. Vincenzi, et al. 2006a. Pulse‐mediated chemotherapy enhances local control and survival in a spontaneous canine model of primary mucosal melanoma. Melanoma Res 16:23–27.
649 Spugnini, E.P., S. Fais, T. Azzarito, et al. 2017. Novel instruments for the implementation of electrochemotherapy protocols: From bench side to veterinary clinic. J Cell Physiol 232:490–495.
650 Spugnini, E.P., B. Vincenzi, B. Amadio, et al. 2019. Adjuvant electrochemotherapy with bleomycin and cisplatin combination for canine soft tissue sarcomas: A study of 30 cases. Open Vet J 9:88–93.
651 Spugnini, E.P., B. Vincenzi, F. Baldi, et al. 2006b. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res 26:4585–4590.
652 Spugnini, E.P., B. Vincenzi, G. Caruso, et al. 2009. Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. J Small Anim Pract 50:44–46.
653 Stanclift, R.M. and S.D. Gilson. 2004. Use of cisplatin, 5‐fluorouracil, and second‐look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. J Am Vet Med Assoc 225:1412–1417, 1393.
654 Stanclift, R.M. and S.D. Gilson. 2008. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 232:53–62.
655 Stefanello, D., G. Avallone, R. Ferrari, et al. 2011. Canine cutaneous perivascular wall tumors at first presentation: Clinical behavior and prognostic factors in 55 cases. J Vet Intern Med 25:1398–1405.
656 Stefanello, D., P. Buracco, S. Sabattini, et al. 2015. Comparison of 2‐ and 3‐category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009–2014). J Am Vet Med Assoc 246:765–769.
657 Stepien, R.L., N.T. Whitley, and R.R. Dubielzig. 2000. Idiopathic or mesothelioma‐related pericardial effusion: Clinical findings and survival in 17 dogs studied retrospectively. J Small Anim Pract 41:342–347.
658 Steplewski, Z., C. Rosales, K.A. Jeglum, et al. 1990. in vivo destruction of canine lymphoma mediated by murine monoclonal antibodies. in vivo 4:231–234.
659 Stone, E.A., T.F. George, S.D. Gilson, et al. 1996. Partial cystectomy for urinary bladder neoplasia: Surgical technique and outcome in 11 dogs. J Small Anim Pract 37:480–485.
660 Stone, M.S., M.A. Goldstein,